Stocks and Investing Stocks and Investing
Wed, March 24, 2021
Tue, March 23, 2021
Mon, March 22, 2021
Fri, March 19, 2021
Thu, March 18, 2021
Wed, March 17, 2021

Gregory Renza Maintained (APRE) at Hold with Decreased Target to $160 on, Mar 17th, 2021


Published on 2024-10-27 15:57:59 - WOPRAI, Gregory Renza
  Print publication without navigation


Gregory Renza of RBC Capital, Maintained "Aprea Therapeutics, Inc." (APRE) at Hold with Decreased Target from $200 to $160 on, Mar 17th, 2021.

Gregory has made no other calls on APRE in the last 4 months.



There are 2 other peers that have a rating on APRE. Out of the 2 peers that are also analyzing APRE, 1 agrees with Gregory's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Jeffrey Hung of "Morgan Stanley" Maintained at Hold with Decreased Target to $680 on, Wednesday, December 16th, 2020


This is the rating of the analyst that currently disagrees with Gregory


  • Esther Hong of "Berenberg" Initiated at Strong Buy and Held Target at $740 on, Wednesday, December 16th, 2020